Outside experts say, however, that the choice of control group in the trial may limit the relevance to clinical practice.

An experimental hormone therapy pill has shown promise in extending the lives of women with tough-to-treat advanced breast ...

The early results presented before the San Antonio Breast Cancer Symposium saw an increased rate of progression-free survival ...

Pfizer (PFE) and Alliance Foundation Trials announced results from the Phase 3 PATINA trial demonstrating that the addition ...

Imlunestrant worked particularly well in combination with the targeted therapy drug Verzenio. The combo helped women with ...

Adding tafasitamab to treatment with lenalidomide and rituximab improved progression-free survival in patients with relapsed or refractory follicular lymphoma.

The FDA issued a second, expanded recall of duloxetine after higher than acceptable levels of a cancer-causing chemical were ...

Patients with heavily pretreated microsatellite stable metastatic colorectal cancer (CRC) had survival benefits after using ...

AstraZeneca and Daiichi Sankyo shared the pooled analysis behind the refiling of their TROP2 antibody-drug conjugate (ADC) ...

Incyte is abandoning its ALK2 blocker zilurgisertib, which it was trialing for myelofibrosis-associated anemia, while iTeos ...

Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy, and ...

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Immutep (IMMP – Research Report), retaining the price target of $12.00.Pick ...